---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-300042"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:40:51.171890+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin settles with Elliott; appoints 3 new directors, forms strategic review committee

## Summary
- Board expanded to 15 directors; appoints Barbara Bodem, Athena Countouriotis, Mark Enyedy as independent directors effective Dec 27, 2023.
- New Strategic and Operating Review Committee chaired by Richard Meier; includes CEO Alexander Hardy and Maykin Ho; to review business, strategy, and capital allocation.
- Cooperation agreement with Elliott includes standstill, voting commitments, and mutual non-disparagement; Elliott supports the changes.
- Company commits to holding an investor day in 2024 after committee recommendations; Elliott entered into information-sharing agreement for JPM conference and earnings.

## SEC filing metadata
- accession: 0001193125-23-300042
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/d488420d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-300042
- JSON: https://secwatch.observer/filing/0001193125-23-300042.json
- Plain text: https://secwatch.observer/filing/0001193125-23-300042.txt

## Key facts
- Executive change
  Barbara Bodem was appointed as director at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: director
  source text: On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm
- Executive change
  Athena Countouriotis was appointed as director at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: director
  source text: On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm
- Executive change
  Mark Enyedy was appointed as director at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: director
  source text: On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm
- Material Agreements
  BIOMARIN PHARMACEUTICAL INC entered into Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”) (effective 2023-12-20).
  - Action: entry
  - Counterparty: Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”)
  - Effective: 2023-12-20
  source text: On December 20, 2023, BioMarin Pharmaceutical Inc. (the “Company”) announced that it had entered into a Cooperation Agreement (the “Cooperation Agreement”) with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, “Elliott”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.